Brigatinib
- ₹0
- Product name: Brigatinib
- CAS: 1197953-54-0
- MF: C29H39ClN7O2P
- MW: 584.09
- EINECS:1592732-453-0
- MDL Number:
- Synonyms:Brigatinib;Brigatinib, AP26113;5-Chloro-N4-[2-(dimethylphosphinyl)phenyl]-N2-[2-methoxy-4-[4-(4-methyl-1-piperazinyl)-1-piperidinyl]phenyl]-2,4-pyrimidinediamine;atinib;Bri atinib ;2,4-Pyrimidinediamine, 5-chloro-N4-[2-(dimethylphosphinyl)phenyl]-N2-[2-methoxy-4-[4-(4-methyl-1-piperazinyl)-1-piperidinyl]phenyl]-;Brigatinib USP/EP/BP;1197953-54-0 Brigatinib
Manufacturer | Product number | Product description | Packaging | Price | Updated | Buy |
---|
Properties
Melting point :>203°C (dec.)
Boiling point :781.8±70.0 °C(Predicted)
Density :1.31±0.1 g/cm3(Predicted)
storage temp. :-20°C
solubility :Soluble in DMSO (1 mg/ml with warming)
form :solid
pka :8.14±0.42(Predicted)
color :White to off-white
Stability :Stable for 2 years from date of purchase as supplied. Solutions in DMSO may be stored at -20°C for up to 1 month.
InChIKey :AILRADAXUVEEIR-UHFFFAOYSA-N
SMILES :C1(NC2=CC=C(N3CCC(N4CCN(C)CC4)CC3)C=C2OC)=NC=C(Cl)C(NC2=CC=CC=C2P(C)(C)=O)=N1
CAS DataBase Reference :1197953-54-0
Boiling point :781.8±70.0 °C(Predicted)
Density :1.31±0.1 g/cm3(Predicted)
storage temp. :-20°C
solubility :Soluble in DMSO (1 mg/ml with warming)
form :solid
pka :8.14±0.42(Predicted)
color :White to off-white
Stability :Stable for 2 years from date of purchase as supplied. Solutions in DMSO may be stored at -20°C for up to 1 month.
InChIKey :AILRADAXUVEEIR-UHFFFAOYSA-N
SMILES :C1(NC2=CC=C(N3CCC(N4CCN(C)CC4)CC3)C=C2OC)=NC=C(Cl)C(NC2=CC=CC=C2P(C)(C)=O)=N1
CAS DataBase Reference :1197953-54-0
Safety Information
Symbol(GHS): | ||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Signal word: | Warning | |||||||||||||||||||||||||||||||||||
Hazard statements: |
|
|||||||||||||||||||||||||||||||||||
Precautionary statements: |
|
Description
Brigatinib is a small molecule inhibitor of both ALK and EGFR [195]. In preclinical models, “triple-mutant EGFR”-positive cells (activating EGFR mutation/ T790M/C797S) responded to the combination of brigatinib with an anti-EGFR monoclonal antibody, cetuximab or panitumumab [196]. Single-agent activity of brigatinib in a phase I/II trial was only 5% [197], possibly compounded by low plasma concentrations [196], but the addition of an anti-EGFR monoclonal antibody remains to be clinically tested. The preclinical data with brigatinib and EAI045?in laboratory models with a C797S mutation demonstrate that combination therapies with an anti-EGFR monoclonal antibody may lead to overcoming resistance to osimertinib.More related product prices
PF-06463922 Crizotinib AP26113 BKM120 (NVP-BKM120, Buparlisib) Ceritinib (LDK378) INCB28060 Olaparib Afatinib (BIBW 2992) Dacomitinib (PF299804) BIBW2992 DiMaleate Enzalutamide (MDV3100) 1-[[4-[(4-Fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]oxy]-2-propanol Pazopanib Everolimus AZD-9291Related product price
- Crizotinib
₹13174.03 - Dacomitinib (PF299804)
₹5000-14200 - Pazopanib
₹7393.48-33730.7